Rapid Induction of Cancer Cell Death by Synergistic Treatment of Tetra-O-methyl Nordihydroguaiaretic Acid (M4N) with either Rottlerin or Ly294002

Case ID:

C10281

Technical Details:
M4N is an anti-cancer drug candidate, which is currently under the first phase of clinical trials. Although M4N can reduce tumor cell growth; it fails to induce quick tumor cell death. JHU scientists showed that the combination treatment of M4N with either two specific kinase inhibitors overcomes this problem. In vivo study demonstrated that the combination treatment reduced tumor metastasis and extended life expectancy of tumor-bearing mice significantly. This combination treatment can be a very important to improve the efficacy of M4N as an anti-cancer drug.
Looking for Partners:
This technology can be used to produce liquid containing M4N with an optimal amount ratio of M4N to either two specific kinase inhibitors. This will allow physicians to prescribe the optimal dosages of this combination treatment to patients.
Patent Status: Issued Patents US 9149526; EP 2240168

Patent Information:

Title	App Type	Country	Serial No.	Patent No.	File Date	Issued Date	Expire Date	Patent Status
Supression of Cancer Growth and Metastasis Using Nordihydroguaiaretic Acid Derivatives with Metabolic Modulators	PCT: Patent Cooperation Treaty	United States	12/812,196	9,149,526	9/30/2010	10/6/2015	1/8/2029	Granted

Direct Link:

https://jhu.technologypublisher.com/technology/16624

Inventors:

Category(s):

Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Therapeutic Modalities,

Get custom alerts for techs in these categories/from these inventors:

Subscribe for JHTV Updates

For Information, Contact:

Nakisha Holder

nickki@jhu.edu

410-614-0300

Save This Technology:

Bookmark this page

Download as PDF